Please enable JavaScript to continue using this application.

Compare $BMRN vs $HALO | Chartloom

Compare

$BMRN vs $HALO

BioMarin Pharmaceutical Inc · Halozyme Therapeutics Inc

BMRN

BioMarin Pharmaceutical Inc

HALO

Halozyme Therapeutics Inc

Compare $BMRN vs $HALO

Comparing BioMarin Pharmaceutical Inc and Halozyme Therapeutics Inc

BMRNBioMarin Pharmaceutical Inc

HALOHalozyme Therapeutics Inc

BMRNBioMarin Pharmaceutical Inc

Market cap

$10.59B

P/E (TTM)

146.03x

Forward P/E (NTM)

12.82x

Forward P/S (NTM)

2.41x

Rev growth (TTM)

11.2%

YTD performance

-7.8%

52W performance

0.2%

FCF yield

6.8%

HALOHalozyme Therapeutics Inc

Market cap

$13.10B

P/E (TTM)

32.36x

Forward P/E (NTM)

10.93x

Forward P/S (NTM)

6.32x

Rev growth (TTM)

41.2%

YTD performance

57.0%

52W performance

69.4%

FCF yield

4.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BMRN

HALO

Detailed metrics comparison

BMRN

BioMarin Pharmaceutical Inc

HALO

Halozyme Therapeutics Inc

Market Cap

BMRN$10.59B

HALO$13.10B

Enterprise Value

BMRN$13.90B

HALO$15.08B

Price

BMRN$54.80

HALO$110.42

P/E Ratio

BMRN146.03x

HALO32.36x

P/S Ratio

BMRN3.11x

HALO7.87x

EV/Sales

BMRN4.08x

HALO9.06x

EV/EBITDA

BMRN16.77x

HALO14.17x

P/B Ratio

BMRN1.75x

HALO86.87x

P/FCF Ratio

BMRN14.61x

HALO25.26x

EV/FCF

BMRN19.17x

HALO29.09x

PEG Ratio

BMRN4.10x

HALO1.08x

Forward P/E (NTM)

BMRN12.82x

HALO10.93x

Forward P/S (NTM)

BMRN2.41x

HALO6.32x

Revenue (TTM)

BMRN$3.41B

HALO$1.66B

Revenue Growth (YoY)

BMRN11.2%

HALO41.2%

Forward Rev Growth

BMRN14.5%

HALO10.9%

Gross Margin (TTM)

BMRN79.6%

HALO82.4%

Operating Margin (TTM)

BMRN4.4%

HALO35.6%

EBITDA Margin (TTM)

BMRN24.3%

HALO63.7%

Net Margin (TTM)

BMRN2.1%

HALO24.9%

FCF Margin (TTM)

BMRN21.3%

HALO31.2%

Net Income (TTM)

BMRN$73M

HALO$414M

FCF (TTM)

BMRN$725M

HALO$518M

EPS (TTM)

BMRN$0.38

HALO$3.41

ROE (TTM)

BMRN1.2%

HALO180.6%

ROA (TTM)

BMRN82.0%

HALO16.6%

ROIC (TTM)

BMRN93.0%

HALO18.7%

Cash

BMRN$874M

HALO$163M

Debt

BMRN$4.19B

HALO$2.15B

Net Cash/Debt

BMRN$-3.31B

HALO$-1.98B

Current Ratio (TTM)

BMRN2.39x

HALO2.71x

Quick Ratio (TTM)

BMRN1.16x

HALO1.99x

Debt/Equity (TTM)

BMRN0.66x

HALO14.95x

Debt/Assets (TTM)

BMRN0.0%

HALO0.0%

Interest Coverage (TTM)

BMRNN/A

HALON/A

Net Debt/EBITDA (TTM)

BMRN0.00x

HALO0.00x

Beta

BMRN0.23

HALO0.94

52W Performance

BMRN0.2%

HALO69.4%

YTD Performance

BMRN-7.8%

HALO57.0%

% from 52W High

BMRN-22.8%

HALO-5.5%

% from 52W Low

BMRN11.2%

HALO80.3%

Asset Turnover (TTM)

BMRN0.38x

HALO0.67x

FCF Yield (TTM)

BMRN6.8%

HALO4.0%

Earnings Yield (TTM)

BMRN0.7%

HALO3.2%

Dividend Yield (TTM)

BMRNN/A

HALON/A

Rule of 40

BMRN32.5

HALO72.3

EV/GP/RG

BMRN0.18

HALO0.44

Ticker research

View BMRN research View HALO research

Metric	BMRN BioMarin Pharmaceutical Inc	HALO Halozyme Therapeutics Inc
Market & Valuation
Market Cap	$10.59B	$13.10B
Enterprise Value	$13.90B	$15.08B
Price	$54.80	$110.42
P/E Ratio	146.03x	32.36x
P/S Ratio	3.11x	7.87x
EV/Sales	4.08x	9.06x
EV/EBITDA	16.77x	14.17x
P/B Ratio	1.75x	86.87x
P/FCF Ratio	14.61x	25.26x
EV/FCF	19.17x	29.09x
PEG Ratio	4.10x	1.08x
Forward P/E (NTM)	12.82x	10.93x
Forward P/S (NTM)	2.41x	6.32x
Revenue & Growth
Revenue (TTM)	$3.41B	$1.66B
Revenue Growth (YoY)	11.2%	41.2%
Forward Rev Growth	14.5%	10.9%
Profitability
Gross Margin (TTM)	79.6%	82.4%
Operating Margin (TTM)	4.4%	35.6%
EBITDA Margin (TTM)	24.3%	63.7%
Net Margin (TTM)	2.1%	24.9%
FCF Margin (TTM)	21.3%	31.2%
Net Income (TTM)	$73M	$414M
FCF (TTM)	$725M	$518M
EPS (TTM)	$0.38	$3.41
ROE (TTM)	1.2%	180.6%
ROA (TTM)	82.0%	16.6%
ROIC (TTM)	93.0%	18.7%
Financial Health
Cash	$874M	$163M
Debt	$4.19B	$2.15B
Net Cash/Debt	$-3.31B	$-1.98B
Current Ratio (TTM)	2.39x	2.71x
Quick Ratio (TTM)	1.16x	1.99x
Debt/Equity (TTM)	0.66x	14.95x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	0.94
52W Performance	0.2%	69.4%
YTD Performance	-7.8%	57.0%
% from 52W High	-22.8%	-5.5%
% from 52W Low	11.2%	80.3%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.67x
FCF Yield (TTM)	6.8%	4.0%
Earnings Yield (TTM)	0.7%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	32.5	72.3
EV/GP/RG	0.18	0.44
Ticker research	View BMRN research	View HALO research

Valuation

P/E Ratio

HALO

32.36x

BMRN

146.03x

P/S Ratio

BMRN

3.11x

HALO

7.87x

EV/FCF

BMRN

19.17x

HALO

29.09x

Growth & revenue

Revenue Growth TTM

HALO

41.2%

BMRN

11.2%

Forward Revenue Growth

BMRN

14.5%

HALO

10.9%

Profitability & performance

Gross Margin

HALO

82.4%

BMRN

79.6%

ROE

HALO

180.6%

BMRN

1.2%

FCF Yield %

BMRN

6.8%

HALO

4.0%

52-Week Performance

HALO

69.4%

BMRN

0.2%

Detailed metrics comparison

BMRN

BioMarin Pharmaceutical Inc

HALO

Halozyme Therapeutics Inc

Market Cap

BMRN$10.59B

HALO$13.10B

Enterprise Value

BMRN$13.90B

HALO$15.08B

Price

BMRN$54.80

HALO$110.42

P/E Ratio

BMRN146.03x

HALO32.36x

P/S Ratio

BMRN3.11x

HALO7.87x

EV/Sales

BMRN4.08x

HALO9.06x

EV/EBITDA

BMRN16.77x

HALO14.17x

P/B Ratio

BMRN1.75x

HALO86.87x

P/FCF Ratio

BMRN14.61x

HALO25.26x

EV/FCF

BMRN19.17x

HALO29.09x

PEG Ratio

BMRN4.10x

HALO1.08x

Forward P/E (NTM)

BMRN12.82x

HALO10.93x

Forward P/S (NTM)

BMRN2.41x

HALO6.32x

Revenue (TTM)

BMRN$3.41B

HALO$1.66B

Revenue Growth (YoY)

BMRN11.2%

HALO41.2%

Forward Rev Growth

BMRN14.5%

HALO10.9%

Gross Margin (TTM)

BMRN79.6%

HALO82.4%

Operating Margin (TTM)

BMRN4.4%

HALO35.6%

EBITDA Margin (TTM)

BMRN24.3%

HALO63.7%

Net Margin (TTM)

BMRN2.1%

HALO24.9%

FCF Margin (TTM)

BMRN21.3%

HALO31.2%

Net Income (TTM)

BMRN$73M

HALO$414M

FCF (TTM)

BMRN$725M

HALO$518M

EPS (TTM)

BMRN$0.38

HALO$3.41

ROE (TTM)

BMRN1.2%

HALO180.6%

ROA (TTM)

BMRN82.0%

HALO16.6%

ROIC (TTM)

BMRN93.0%

HALO18.7%

Cash

BMRN$874M

HALO$163M

Debt

BMRN$4.19B

HALO$2.15B

Net Cash/Debt

BMRN$-3.31B

HALO$-1.98B

Current Ratio (TTM)

BMRN2.39x

HALO2.71x

Quick Ratio (TTM)

BMRN1.16x

HALO1.99x

Debt/Equity (TTM)

BMRN0.66x

HALO14.95x

Debt/Assets (TTM)

BMRN0.0%

HALO0.0%

Interest Coverage (TTM)

BMRNN/A

HALON/A

Net Debt/EBITDA (TTM)

BMRN0.00x

HALO0.00x

Beta

BMRN0.23

HALO0.94

52W Performance

BMRN0.2%

HALO69.4%

YTD Performance

BMRN-7.8%

HALO57.0%

% from 52W High

BMRN-22.8%

HALO-5.5%

% from 52W Low

BMRN11.2%

HALO80.3%

Asset Turnover (TTM)

BMRN0.38x

HALO0.67x

FCF Yield (TTM)

BMRN6.8%

HALO4.0%

Earnings Yield (TTM)

BMRN0.7%

HALO3.2%

Dividend Yield (TTM)

BMRNN/A

HALON/A

Rule of 40

BMRN32.5

HALO72.3

EV/GP/RG

BMRN0.18

HALO0.44

Ticker research

View BMRN research View HALO research

Metric	BMRN BioMarin Pharmaceutical Inc	HALO Halozyme Therapeutics Inc
Market & Valuation
Market Cap	$10.59B	$13.10B
Enterprise Value	$13.90B	$15.08B
Price	$54.80	$110.42
P/E Ratio	146.03x	32.36x
P/S Ratio	3.11x	7.87x
EV/Sales	4.08x	9.06x
EV/EBITDA	16.77x	14.17x
P/B Ratio	1.75x	86.87x
P/FCF Ratio	14.61x	25.26x
EV/FCF	19.17x	29.09x
PEG Ratio	4.10x	1.08x
Forward P/E (NTM)	12.82x	10.93x
Forward P/S (NTM)	2.41x	6.32x
Revenue & Growth
Revenue (TTM)	$3.41B	$1.66B
Revenue Growth (YoY)	11.2%	41.2%
Forward Rev Growth	14.5%	10.9%
Profitability
Gross Margin (TTM)	79.6%	82.4%
Operating Margin (TTM)	4.4%	35.6%
EBITDA Margin (TTM)	24.3%	63.7%
Net Margin (TTM)	2.1%	24.9%
FCF Margin (TTM)	21.3%	31.2%
Net Income (TTM)	$73M	$414M
FCF (TTM)	$725M	$518M
EPS (TTM)	$0.38	$3.41
ROE (TTM)	1.2%	180.6%
ROA (TTM)	82.0%	16.6%
ROIC (TTM)	93.0%	18.7%
Financial Health
Cash	$874M	$163M
Debt	$4.19B	$2.15B
Net Cash/Debt	$-3.31B	$-1.98B
Current Ratio (TTM)	2.39x	2.71x
Quick Ratio (TTM)	1.16x	1.99x
Debt/Equity (TTM)	0.66x	14.95x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	0.94
52W Performance	0.2%	69.4%
YTD Performance	-7.8%	57.0%
% from 52W High	-22.8%	-5.5%
% from 52W Low	11.2%	80.3%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.67x
FCF Yield (TTM)	6.8%	4.0%
Earnings Yield (TTM)	0.7%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	32.5	72.3
EV/GP/RG	0.18	0.44
Ticker research	View BMRN research	View HALO research